The electrophysiological properties of ranolazine: A metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?

Reviews in Cardiovascular Medicine

Volumn 12, Issue 3, 2011, Pages 136-142

  Cingolani, Eugenio ^a   Lepor, Norman E ^a   Singh, Bramah N ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Anti ischemic agents; Mechanisms of arrhythmias; Ranolazine

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; AMIODARONE; CALCIUM; DRONEDARONE; IVABRADINE; NITRENDIPINE; PLACEBO; RANOLAZINE; TRIMETAZIDINE; ACETANILIDE DERIVATIVE; ANTIARRHYTHMIC AGENT; PIPERAZINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; CARDIAC PATIENT; CHRONIC DISEASE; FATTY ACID OXIDATION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PAPILLARY MUSCLE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; QT PROLONGATION; REPERFUSION INJURY; REVIEW; STABLE ANGINA PECTORIS; ANIMAL; DRUG EFFECT; ENERGY METABOLISM; HEART ARRHYTHMIA; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; PATHOPHYSIOLOGY;

ACETANILIDES; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ENERGY METABOLISM; HEART CONDUCTION SYSTEM; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PIPERAZINES;

EID: 84855376613     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0572     Document Type: Review

References (45)

1. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970;39:657-667.
2. Singh BN, Jewitt DE, Downey JM, et al. Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials. Clin Exp Pharmacol Physiol. 1976;3:427-442.
3. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J. 1983; 106(4 Pt 2):788-797. (Pubitemid 13010812)
4. Singh BN, Singh SN, Reda DJ, et al Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
5. Singh SN, Singh BN, Reda DJ, et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol. 2003;92: 468-472. (Pubitemid 36959890)
6. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994;121: 529-535.
7. Goldschmidt M, Frishman WH. Ranolazine: a new anti-ischemic drug which affects myocardial energetics. Am J Ther. 1995;2:269-274.
8. Wyatt KM, Skene C, Veitch K, et al. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol. 1995; 50:1599-1606.
9. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93:135-142. (Pubitemid 26007542)
10. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001;418:105-110. (Pubitemid 32378816)
11. Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2002;8:416-422. (Pubitemid 36055744)
12. Chaitman BR, Pepine CJ, Parker JO, et al Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004; 291:309-316. (Pubitemid 38101603)
13. Chaitman BR, Skettino SL, Parker JO, et al MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43: 1375-1382. (Pubitemid 38496341)
14. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004; 110:904-910. (Pubitemid 39136212)
15. Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol. 1996;118:249-254. (Pubitemid 26149270)
16. Hasenfuss G, Maier LS. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol. 2008;97:222-226. (Pubitemid 351467616)
17. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation. 1999;99:2829-2848. (Pubitemid 29250032)
18. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393-405. (Pubitemid 46425552)
19. Horinaka S, Yabe A, Yagi H, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2010;74:503-509.
20. Kuno A, Critz SD, Cohen MV, Downey JM. Nicorandil opens mitochondrial K(ATP) channels not only directly but also through a NO-PKG-dependent pathway. Basic Res Cardiol. 2007;102:73-79. (Pubitemid 44939336)
21. Nakayama K, Fan Z, Marumo F, et al. Action of nicorandil on ATP-sensitive K+ channel in guinea-pig ventricular myocytes. Br J Pharmacol. 1991;103:1641-1648.
22. Nagata K, Obata K, Odashima M, et al. Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. J Mol Cell Cardiol. 2003;35:1505-1512. (Pubitemid 37491193)
23. Teshima Y, Akao M, Baumgartner WA, Marbán E. Nicorandil prevents oxidative stress-induced apoptosis in neurons by activating mitochondrial ATP-sensitive potassium channels. Brain Res. 2003;990:45-50. (Pubitemid 37244060)
24. Mouquet F, Rousseau D, Domergue-Dupont V, et al. Effects of trimetazidine, a partial inhibitor of fatty acid oxidation, on ventricular function and survival after myocardial infarction and reperfusion in the rat. Fundam Clin Pharmacol. 2010;24:469-476.
25. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580-588. (Pubitemid 30165050)
26. Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2008;15: 533-540.
27. Grabczewska Z, Białoszyński T, Szymański P, et al. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease. Cardiol J. 2008;15:344-350.
28. Mehrotra TN, Bassadone ET. Trimetazidine in the treatment of angina pectoris. Br J Clin Pract. 1967;21:553-554.
29. Zemljic G, Bunc M, Vrtovec B. Trimetazidine shortens QTc interval in patients with ischemic heart failure. J Cardiovasc Pharmacol Ther. 2010;15:31-36.
30. Hale SL, Kloner RA. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther. 2006;11: 249-255. (Pubitemid 44936238)
31. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205. (Pubitemid 34059525)
32. White RD, Wood DL. Out-of-hospital pleomorphic ventricular tachycardia and resuscitation: association with acute myocardial ischemia and infarction. Ann Emerg Med. 1992;21: 1282-1287.
33. O'Rourke B, Ramza BM, Marban E. Oscillations of membrane current and excitability driven by metabolic oscillations in heart cells. Science. 1994;265:962-966. (Pubitemid 24281495)
34. Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest. 2005;115:3527-3535. (Pubitemid 43121840)
35. Marban E, Robinson SW, Wier WG. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J Clin Invest. 1986;78:1185-1192. (Pubitemid 17181555)
36. Singh BN, Vanhhouette PN. Selective and Specific IF Inhibition in Cardiovascular Disease. 1st ed. London, UK: Lippincott Williams & Wilkins; 2003.
37. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-666. (Pubitemid 28402090)
38. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008;5:1019-1026.
39. Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56: 1216-1224.
40. Sicouri S, Timothy KW, Zygmunt AC, et al. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm. 2007;4:638-647. (Pubitemid 46630371)
41. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007; 116:1647-1652. (Pubitemid 47537839)
42. Antzelevitch C. Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes? Nat Clin Pract Cardiovasc Med. 2008;5:248-249. (Pubitemid 351605834)
43. Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9:260-267.
44. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-1783. (Pubitemid 46658646)
45. Bagger JP, Botker HE, Thomassen A, Nielsen TT. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther. 1997;11:479-484. (Pubitemid 27367713)